Stem cell chief's exit is long overdue
By Editorial,
Sacramento Bee
| 06. 20. 2009
Palo Alto developer Robert Klein II led the ballot campaign in 2004 to create California's stem cell research institute. He wrote the initiative, ensuring that only he would chair the institute's oversight board, which is charged with handling $3 billion in public money.
For more than four years, this page has detailed how Klein's all-powerful control has not been in the best interest of either taxpayers or the stem cell agency, the California Institute for Regenerative Medicine.
Now it appears that Klein will step down from CIRM at the end of 2010 – more than 18 months away.
Klein is an impassioned, tenacious advocate for stem cell research, but he is precisely the wrong person to head a government science agency. Chairing a 29-member board that is far too large and rife with conflicts of interest, Klein has operated the institute in a smothering manner, with little regard to transparency or lines of authority.
Since 2005, Klein has run off talented scientists, such as former CIRM President Zach Hall. He has helped direct millions of dollars to contracts for law...
Related Articles
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Staff, The Associated Press | 06.10.2025
PORTLAND, Ore. — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks...